CVRx, Inc. (CVRX) stock
CVRXNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
$0.61−0.02 (-3.60%)
Close on Nov 13, 2026Market cap $16.18MP/E –Yield –
CVRx r&d expenses
Research and development expenses are spending on new products and technology.
CVRx's R&D Expenses for the twelve months ending Sep 30, 2026 was $11.87M, up 8.5% year over year. For fiscal 2025 it was $11.13M, up 0.0% from the year before. The highest annual figure on record is $11.63M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.13M | +0.0% |
| FY2024 | Dec 31, 2024 | $11.13M | -4.3% |
| FY2023 | Dec 31, 2023 | $11.63M | +16.9% |
| FY2022 | Dec 31, 2022 | $9.95M | +32.7% |
| FY2021 | Dec 31, 2021 | $7.50M | +17.0% |
| FY2020 | Dec 31, 2020 | $6.41M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $2.66M | -15.6% |
| Q2 FY2026 | Jun 30, 2026 | $3.13M | +26.8% |
| Q1 FY2026 | Mar 31, 2026 | $3.08M | +22.5% |
| Q4 FY2025 | Dec 31, 2025 | $3.00M | +7.0% |
| Q3 FY2025 | Sep 30, 2025 | $3.15M | +25.6% |
| Q2 FY2025 | Jun 30, 2025 | $2.47M | -10.7% |
| Q1 FY2025 | Mar 31, 2025 | $2.52M | -17.7% |
| Q4 FY2024 | Dec 31, 2024 | $2.81M | +25.2% |
| Q3 FY2024 | Sep 30, 2024 | $2.50M | -7.1% |
| Q2 FY2024 | Jun 30, 2024 | $2.77M | -15.7% |
| Q1 FY2024 | Mar 31, 2024 | $3.06M | -10.5% |
| Q4 FY2023 | Dec 31, 2023 | $2.24M | -26.4% |
| Q3 FY2023 | Sep 30, 2023 | $2.70M | +17.6% |
| Q2 FY2023 | Jun 30, 2023 | $3.28M | +39.3% |
| Q1 FY2023 | Mar 31, 2023 | $3.42M | +51.3% |
| Q4 FY2022 | Dec 31, 2022 | $3.05M | +69.5% |
| Q3 FY2022 | Sep 30, 2022 | $2.29M | +35.0% |
| Q2 FY2022 | Jun 30, 2022 | $2.36M | +4.4% |
| Q1 FY2022 | Mar 31, 2022 | $2.26M | +29.0% |
| Q4 FY2021 | Dec 31, 2021 | $1.80M | +252.4% |
| Q3 FY2021 | Sep 30, 2021 | $1.70M | +13.3% |
| Q2 FY2021 | Jun 30, 2021 | $2.26M | +5.8% |
| Q1 FY2021 | Mar 31, 2021 | $1.75M | – |
| Q4 FY2020 | Dec 31, 2020 | $510.00K | – |
| Q3 FY2020 | Sep 30, 2020 | $1.50M | – |
| Q2 FY2020 | Jun 30, 2020 | $2.13M | – |
See a number that looks wrong?